BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
for Clinical Stage III Cutaneous Melanoma AJCC v8
Drug: Cabozantinib
222 locations incl. Phoenix
Sponsor: National Cancer Institute (NCI)
Sex: All·Age: 18+
Code: NCT05136196·Phase 2·Recruiting